External consultants have evaluated the situation and assessed that Peptonic has strong prospects of being granted the restructuring, the company states. The company acknowledges the potential impact on suppliers, customers, and partners but emphasizes that the measures being taken are unavoidable to secure its future and establish a stable and profitable business, it states.

Anders Blom, Chairman, Peptonic Medical

“The decision to apply for corporate restructuring has not been taken lightly. However, it is a crucial step in addressing the company’s financial challenges and creating a solid foundation for the future. We are confident that this process will provide the best conditions for recovery, allowing us to strengthen our financial stability and ensure sustainable growth,” says Anders Blom, Chairman of the Board.

The restructuring application is now subject to approval by the District Court. If granted, the process is expected to be completed within the next three to six months. During this period, Peptonic will implement financial and operational adjustments to build a resilient and profitable business for the future.